RLAY Relay Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1812364 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY23.9%
TTM net income YoY1.3%
TTM EPS YoY12.8%
Revenue 3-yr CAGR-26.2%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-3,094.6%
Net margin-2,837.0%
FCF margin—
EBITDA margin-3,077.7%
Returns
ROE-41.2%
ROA-37.4%
ROIC (approx.)-41.8%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets9.2%
Debt / equity0.00x
Current ratio14.62x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.73x
Accruals ratio-10.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q3*2026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $350,000 | $3.00M | $7.00M | $0 | $677,000 | $7.68M | $0 |
| R&D expense | $77.14M | $76.48M | $70.56M | $55.41M | $68.26M | $63.90M | $73.81M | $68.08M |
| SG&A expense | $13.11M | $14.69M | $11.03M | $12.21M | $12.13M | $13.63M | $18.74M | $16.90M |
| Operating income | -$90.25M | -$90.82M | -$78.59M | -$60.63M | -$80.39M | -$76.85M | -$84.87M | -$84.98M |
| Net income | -$81.75M | -$83.71M | -$73.29M | -$54.89M | -$74.15M | -$70.38M | -$77.06M | -$76.00M |
| EBITDA | -$89.97M | -$90.46M | -$78.09M | -$60.03M | -$79.64M | -$75.84M | -$83.66M | -$83.64M |
| EPS (basic) | -0.37 | -0.41 | -0.41 | — | -0.43 | -0.41 | -0.46 | — |
| EPS (diluted) | -0.37 | -0.41 | -0.41 | — | -0.43 | -0.41 | -0.46 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $124.18M | $121.19M | $204.59M | $84.02M | $91.56M | $113.94M | $93.54M | $126.41M |
| Current assets | $864.85M | $928.08M | $658.46M | $578.28M | $624.01M | $680.39M | $739.66M | $809.20M |
| PP&E, net | $582,000 | $862,000 | $1.22M | $1.73M | $2.36M | $3.46M | $5.15M | $5.91M |
| Intangibles | $4.75M | — | — | — | — | — | — | — |
| Total assets | $901.69M | $967.46M | $699.61M | $621.33M | $670.00M | $728.84M | $799.36M | $871.30M |
| Current liabilities | $59.15M | $50.80M | $29.75M | $25.58M | $32.60M | $32.52M | $37.05M | $50.73M |
| Total liabilities | $82.70M | $77.45M | $57.43M | $54.27M | $62.29M | $63.18M | $78.28M | $93.50M |
| Shareholders' equity | $819.00M | $890.01M | $642.18M | $567.06M | $607.71M | $665.66M | $721.08M | $777.79M |
| Shares outstanding | 219.50M | 218.53M | 189.21M | 173.87M | 172.63M | 171.69M | 170.48M | 167.76M |
| Cash flow statement | ||||||||
| Operating cash flow | -$63.93M | -$54.11M | -$51.11M | -$44.87M | -$62.12M | -$55.26M | -$73.21M | -$57.87M |
| Capital expenditure | $0 | — | — | $1,000 | -$1,000 | $26,000 | $384,000 | $0 |
| Free cash flow | -$63.93M | — | — | -$44.87M | -$62.12M | -$55.29M | -$73.59M | -$57.87M |
| Investing cash flow | $62.37M | -$353.03M | $32.90M | $35.46M | $39.73M | $75.15M | $42.47M | $29.00M |
| Financing cash flow | $4.42M | $323.74M | $138.78M | $934,000 | $17,000 | — | — | $800,000 |
| Depreciation & amortization | $280,000 | $360,000 | $504,000 | $599,000 | $748,000 | $1.00M | $1.21M | $1.33M |
| Stock-based compensation | $10.12M | $9.18M | $10.54M | $13.07M | $15.53M | $14.50M | $19.32M | $17.64M |
Free plan shows the latest 8 periods; Pro shows all 31 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.